Jefferies Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jefferies Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,500	Closed	-$655K	–	1434
2024 Q1	$655K	Sell	7,500 -29,000	-79%	-$2.6M	0.01%	960
2023 Q4	$3.52M	Buy	36,500 +14,200	+64%	+$1.26M	0.02%	512
2023 Q3	$1.97M	Buy	22,300 +12,300	+123%	+$1.09M	0.02%	628
2023 Q2	$867K	Hold	10,000	–	–	0.01%	981
2023 Q1	$972K	Sell	10,000 -5,100	-34%	-$529K	0.01%	904
2022 Q4	$1.56M	Buy	+15,100	New	+$1.42M	0.01%	740

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Financial Group's BMRN Position: Q1 2026 in Review

Jefferies Financial Group increased its BioMarin Pharmaceuticals (BMRN) stake by 0.24% in Q1 2026, buying an estimated $65.8K and bringing the position to 468,146 shares worth $26.4M. The position accounts for 0.18% of the portfolio, ranked #89.

Jefferies Financial Group first reported a position in BMRN in Q4 2022 and has held it in 10 quarters since. The position peaked at $27.8M in Q4 2025. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Jefferies Financial Group held 468,146 shares of BioMarin Pharmaceuticals worth $26.4M as of Q1 2026.
Jefferies Financial Group bought 1,128 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $65.8K.
BioMarin Pharmaceuticals made up 0.18% of Jefferies Financial Group's portfolio in Q1 2026, its #89 holding.
Jefferies Financial Group first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
Jefferies Financial Group's BioMarin Pharmaceuticals position peaked at $27.8M in Q4 2025.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.